Selectively altering microbiota for immune modulation
AssigneeSNIPR Technologies Limited
InventorJasper Clube
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
Claims22
A method for treating an infectious disease in a human patient, wherein the method comprises
- (a) exposing a microbiota in the patient to a guided nuclease to selectively target the genome of cells of a first species in the microbiota using the guided nuclease, wherein the first species is a bacterial or archaeal species;
- and simultaneously or sequentially administering to the patient an effective amount of an immunotherapy;
- and
- (b) allowing the guided nuclease to cut one or more target nucleotide sequences comprised by first cells of a first strain of the first species, thereby killing the first cells or reducing the growth thereof, whereby the proportion of the first cells comprised by the microbiota is reduced;
- wherein
- (c) the selective targeting avoids targeting second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the first cells, wherein the second cells are probiotic, commensal or symbiotic with humans;
- and
- (d) the reducing of the proportion of the first cells modulates immune cells in the patient, whereby the efficacy of the immunotherapy is enhanced for treatment of the infectious disease in the patient.
Dependencies are inferred from the claim text.